| Literature DB >> 33359413 |
Neelam Yadav1, Jagriti Narang2, Anil Kumar Chhillar3, Jogender Singh Rana4.
Abstract
Infectious and hereditary diseases are the primary cause of human mortality globally. Applications of conventional techniques require significant improvement in sensitivity and specificity in therapeutics. However, clustered regularly interspaced short palindromic repeats (CRISPRs) is an innovative genome editing technology which has provided a significant therapeutic tool exhibiting high sensitivity, fast and precise investigation of distinct pathogens in an epidemic. CRISPR technology has also facilitated the understanding of the biology and therapeutic mechanism of cancer and several other hereditary diseases. Researchers have used the CRISPR technology as a theranostic approach for a wide range of diseases causing pathogens including distinct bacteria, viruses, fungi and parasites and genetic mutations as well. In this review article, besides various therapeutic applications of infectious and hereditary diseases we have also explained the structure and mechanism of CRISPR tools and role of CRISPR integrated biosensing technology in provoking diagnostic applications.Entities:
Keywords: Biosensing technology; CRISPR technology; Cancer; Cardiovascular diseases; Infectious diseases
Mesh:
Year: 2021 PMID: 33359413 PMCID: PMC7831819 DOI: 10.1016/j.nano.2020.102350
Source DB: PubMed Journal: Nanomedicine ISSN: 1549-9634 Impact factor: 5.307
Figure 1Diagrammatic illustration of mechanism of structural components of CRISPR-Cas system.
Figure 2Bacterial therapeutic applications of CRISPR-Cas system.
Figure 3CRISPR based diagnostic significance for infectious diseases.
Figure 4Therapeutic applications of CRISPR-Cas system in cancer.
Application of CRISPR-Cas9 system in cancer therapeutics.
| Sr. no. | Name of cancer | Target cell/tissue/organ | Target gene | Application/advantage | Name of cell line | Strategy used | Reference |
|---|---|---|---|---|---|---|---|
| 1. | Breast | - | BRCA1m and PARP1m | Screening of doxorubicin, gemcitabine and docetaxel chemotherapeutic drugs | MDA-MB-231 and MDA-MB-436 | Deletion of genes | |
| 2. | Refractory | Mouse T cells | TRAC, TRBC and PDCD1 | Increased stability of T cells | HLA-A*0201 and | Gene editing by chromosomal translocation | |
| 3. | Leukemia | Murine acute myeloid leukemia cells, U6-sgRNA-EFS-GFP or the U6-sgRNA-EFS-mCherry plasmids | Discovering therapeutic targets in cancer | HEK293T cells, MLL-AF9/NrasG12D acute myeloid leukemia , MSCV-hCas9-PGK-Puro and RPMI1640 | Genome editing | ||
| 4. | Colorectal adenocarcinoma | Chondrocytes of mice | MMP3 and CCN2/CTGF | Inhibition of metastatic tumor in vitro and in vivo | Chondrosarcoma-derived chondrocytic cell line HCS-2/8, MDA-MB-231 | Genome editing | |
| 5. | Breast cancer | Breast cancer cells | Study the phylogenetic relationships among breast cancer subtypes as stratified by cancer stemness | MCF7, SKBR3 and MDAMB231 | Genome editing by overexpressing of | ||
| 6. | Colon organoids | Human colonic stem cells | mismatch repair gene MLH1 | Explore the origin of cancer-associated mutational signatures | MLH1KO and NTHL1KO | Delete key DNA repair genes followed by delayed subcloning and whole-genome sequencing |
Figure 5Therapeutic applications of CRISPR-Cas system in cardiovascular diseases.
Applications of CRISPR-Cas9 system in cardiovascular diseases.
| Sr. no. | Name of cardiovascular diseases | Target cell/tissue/organ | Target gene | Application | Name model organism | Vector used | Reference |
|---|---|---|---|---|---|---|---|
| 1. | Cardiomyopathy | Cardiomyocytes | Myh6 | Demonstrated the role of Myh6 in heart function | Mice | Adeno-associated virus | |
| 2. | Atherosclerosis | Embryo | Apolipoprotein E ( | To study human cardiovascular disease by accessing the level of biochemical constituents | Pigs | Genome editing | |
| Fibroblast and myoblast | Controlling transcription in cardiomyocytes of the postnatal heart | Mice | Genome editing | ||||
| 3. | Cardiac dysfunction | Lineage-negative bone marrow cells | TET2 and Dnmt3a | Role of targeted genes in cardiac dysfunction and renal fibrosis | Mice | Lentivirus | |
| 4. | Duchenne muscular dystrophy | C2C12 mouse myoblasts | Restoration of dystrophin protein expression | Mice | Adeno-associated virus | ||
| 5. | Atherosclerosis | Hepatocytes | Low-density lipoprotein receptor (LDLR) | Effective therapeutic approach for the treatment of familial hypercholesterolemia | Mice | Adeno-associated virus |
Figure 6Therapeutic applications of CRISPR-Cas system in diabetes.
Figure 7Therapeutic neurological applications of CRISPR-Cas system.